Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncolytics Biotech Inc. -- Ignore unavailable to you. Want to Upgrade?

To: geoffb_si who wrote (76)	4/27/2002 8:28:26 PM
From: DaveAu	Read Replies (1) \| Respond to of 103

Geoff, I've noted that ONXX has made a big move up recently (despite some negative analyst comments) on a couple of favourable articles in the US general interest press but none of it has spilled over to ONC. I believe the ONC virus has huge advantages over competitors although some like ONXX are a little further ahead (although this may be deceiving). The ONC virus causes no human disease, is the easiest to manufacture (witness their primate studies and also notes form the annual report), is useful against a wider range of cancers, and seems to be more effective (based on animal and admittedly small initial human trial). Unfortunately, the biotech market sucks right now and I notice Barrons this week is saying that large biotechs are overvalued which won't help the sector. It'll be interesting to see on Monday if this article brings more interest to ONC. Dave